{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:04:23Z","timestamp":1783533863967,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1378\/chest.127.3.818","type":"journal-article","created":{"date-parts":[[2005,3,12]],"date-time":"2005-03-12T01:58:48Z","timestamp":1110592728000},"page":"818-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Detrimental Effects of \u03b2-Blockers in COPD"],"prefix":"10.1016","volume":"127","author":[{"given":"Hanneke J","family":"van der Woude","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Zaagsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirkje S","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trea H","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus","family":"van Hulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e8","family":"Aalbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.127.3.818_bib1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990\u20132020: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.127.3.818_bib2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective \u03b2-blockers for chronic obstructive pulmonary disease: a meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir Med"},{"key":"10.1378\/chest.127.3.818_bib3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(00)02815-4","article-title":"Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study","volume":"356","author":"Hospers","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.127.3.818_bib4","first-page":"276","article-title":"Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction","volume":"134","author":"Postma","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.127.3.818_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1164\/ajrccm.153.6.8665038","article-title":"Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group","volume":"153","author":"Tashkin","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.818_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/thx.40.6.422","article-title":"Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis","volume":"40","author":"Ramsdale","year":"1985","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.818_bib7","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/thx.39.12.912","article-title":"Bronchial hyperresponsiveness to methacholine in chronic bronchitis: relationship to air flow obstruction and cold air responsiveness","volume":"39","author":"Ramsdale","year":"1984","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.818_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1399-3003.1999.14b08.x","article-title":"Tolerance of \u03b2 agonists during acute bronchoconstriction","volume":"14","author":"Hancox","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.127.3.818_bib9","unstructured":"Executive Summary NHLBI\/WHO Workshop Report: Global Strategy for the Diagnosis, Management and Prevention of COPD. Bethesda, MD: National Heart, Lung and Blood Institute 2001; NIH Publication No 2701A"},{"key":"10.1378\/chest.127.3.818_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/pupt.2000.0267","article-title":"Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD","volume":"14","author":"Cazzola","year":"2001","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1378\/chest.127.3.818_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.127.3.818_bib12","doi-asserted-by":"crossref","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows: Report Working Party Standardisation of Lung Function Tests European Community of Steel and Coal; Official Statement of the European Respiratory Society. Eur Respir J 1993; 6(Suppl):5\u201340","DOI":"10.1183\/09041950.005s1693"},{"key":"10.1378\/chest.127.3.818_bib13","unstructured":"Farmacotherapeutisch Compas. Medische Farmaceutische Voorlichting. Ziekenfondsraad 2004 Amstelveen, the Netherlands"},{"key":"10.1378\/chest.127.3.818_bib14","first-page":"529","article-title":"Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long-acting \u03b22agonists","volume":"56","author":"Van der Woude","year":"2001","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.818_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2125.1978.tb01608.x","article-title":"Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction","volume":"5","author":"Perks","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.127.3.818_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF00556885","article-title":"Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade","volume":"27","author":"Clague","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1378\/chest.127.3.818_bib17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1164\/ajrccm.159.4.9807121","article-title":"Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease","volume":"159","author":"Hansen","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.818_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7326\/0003-4819-137-9-200211050-00035","article-title":"Cardioselective \u03b2-blockers in patients with reactive airway disease: a meta-analysis","volume":"137","author":"Salpeter","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.127.3.818_bib19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1034\/j.1399-3003.1999.13e10.x","article-title":"Comparison of formoterol, salbutamol and salmeterol in methacholine induced severe bronchoconstriction","volume":"13","author":"Politiek","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.127.3.818_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/bja\/39.12.919","article-title":"The effect of propranolol on airway resistance","volume":"39","author":"Macdonald","year":"1967","journal-title":"Br J Anaesthesiol"},{"key":"10.1378\/chest.127.3.818_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1183\/09041950.053s1693","volume":"16","author":"Sterk","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"10.1378\/chest.127.3.818_bib22","doi-asserted-by":"crossref","unstructured":"COPD guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary diseases. Thorax 1997; 52(suppl):S1\u2013S28","DOI":"10.1136\/thx.52.2008.S1.5"},{"key":"10.1378\/chest.127.3.818_bib23","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1183\/09031936.95.08081398","article-title":"Optimal assessment and management of chronic obstructive pulmonary disease (COPD)","volume":"8","author":"Siafakas","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.127.3.818_bib24","first-page":"S77","article-title":"Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease","volume":"152","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.127.3.818_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/thorax.58.8.659","article-title":"Bronchodilator reversibility testing in chronic obstructive pulmonary disease","volume":"58","author":"Calverley","year":"2003","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.818_bib26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/thorax.58.8.647","article-title":"Responses to steroids and bronchodilators in COPD in the ISOLDE trial: the fat lady sings on","volume":"58","author":"Gross","year":"2003","journal-title":"Thorax"},{"key":"10.1378\/chest.127.3.818_bib27","doi-asserted-by":"crossref","first-page":"14C","DOI":"10.1016\/0002-9149(88)90479-1","article-title":"Anti-hypertensive therapy with celiprolol: a new cardioselective \u03b2-blocker","volume":"61","author":"Norris","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.127.3.818_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1378\/chest.121.1.230","article-title":"The pharmacological treatment of uncomplicated arterial hypertension in patients with airway dysfunction","volume":"121","author":"Cazzola","year":"2002","journal-title":"Chest"},{"key":"10.1378\/chest.127.3.818_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1378\/chest.123.1.222","article-title":"Treatment of systemic hypertension in patients with pulmonary diseases: COPD and asthma","volume":"123","author":"Dart","year":"2003","journal-title":"Chest"},{"key":"10.1378\/chest.127.3.818_bib30","doi-asserted-by":"crossref","first-page":"15J","DOI":"10.1016\/S0002-9149(97)00833-3","article-title":"Clinical relevance of pharmacokinetic differences between \u03b2-blockers","volume":"80","author":"Kendall","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.127.3.818_bib31","doi-asserted-by":"crossref","unstructured":"Kendall MJ. Possible mechanism of action in the positive effect of \u03b2 blockers in heart failure. Heart 1999; 82(suppl): IV5\u2013IV7","DOI":"10.1136\/hrt.82.2008.iv5"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215310898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215310898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:43:34Z","timestamp":1757918614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215310898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0012369215310898"],"URL":"https:\/\/doi.org\/10.1378\/chest.127.3.818","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detrimental Effects of \u03b2-Blockers in COPD","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.127.3.818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}